TENAX THERAPEUTICS, INC.

CIK 34956’s Tenax Therapeutics, Inc., trading as TENX, positions itself as a clinical-stage pharmaceutical developer focused on advanced formulations for acute respiratory and inflammatory conditions, blending rapid-onset delivery technologies with specialty chemical manufacturing that falls within SIC 2834’s pharmaceutical preparations context; its core services are centered on advancing investigational products through late-stage studies and partnering with hospital systems, pulmonologists, and acute care clinics that treat patients with pulmonary hypertension, refractory cough, and other distressing lung ailments, while its commercial strategy keeps a lean manufacturing partner network ready to scale if regulators sign off. Tenax must manage the usual material risks of the biopharma sector—clinical trial outcomes, FDA and foreign approval timelines, supply-chain fragility, and pricing/coverage scrutiny—plus the heightened compliance requirements tied to narcotics-controls and post-market surveillance; given the latest filing status is unknown, stakeholders are watching for updated disclosures. View live SEC filings on Earnings Feed.

Source: Earnings Feed research · last updated 11/24/2025